Vetmedin
Country: Italy
Language: English
Source: HMA (Heads of Medicines Agencies)
Patient Information leaflet
(PIL)
31-08-2013
Summary of Product characteristics
(SPC)
31-08-2013
Active ingredient:
pimobendan 1.25 mg
Available from:
Boehringer Ingelheim Vetmedica GmbH
ATC code:
QC01CE90
Pharmaceutical form:
Chewable tablet
Therapeutic group:
pimobendane
Therapeutic area:
Dogs
Authorization date:
2012-01-27
Patient Information leaflet
1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 1.25 mg chewable tablets for dogs
(AT, BG, CY, CZ, EE, EL, HU, LV, LT, PL, RO, SI, SK, ES, IS, LI, PT, BE, LU, NL)
[Pimobendan Vetmedica 1.25 mg chewable tablets for dogs
(FI, FR, IE, IT, SE, UK)
Pimobendan Boehringer Ingelheim Vetmedica GmbH 1.25 mg chewable tablets for dogs
(NO)
The name ‘the product’ will be used in the Product Information]
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One chewable tablet contains:
ACTIVE SUBSTANCE:
Pimobendan
1.25 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet.
Oblong, scored, mottled brown tablets with fine white spots, embossed with Boehringer Ingelheim
logo and P01.
The tablet can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or
valvular insufficiency (mitral and/or tricuspid valve regurgitation).
(See also section 4.9).
4.3
CONTRAINDICATIONS
[The product] is not to be used in hypertrophic cardiomyopathies or in diseases in which an
improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic
stenosis).
Since [the product] is metabolised mainly via the liver, it should not be used in dogs with severe
impairment of liver function (see also 4.7).
3
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PREC
Read the complete document
Summary of Product characteristics
1
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE VETERINARY MEDICINAL PRODUCT
Vetmedin 1.25 mg chewable tablets for dogs
(AT, BG, CY, CZ, EE, EL, HU, LV, LT, PL, RO, SI, SK, ES, IS, LI, PT, BE, LU, NL)
[Pimobendan Vetmedica 1.25 mg chewable tablets for dogs
(FI, FR, IE, IT, SE, UK)
Pimobendan Boehringer Ingelheim Vetmedica GmbH 1.25 mg chewable tablets for dogs
(NO)
The name ‘the product’ will be used in the Product Information]
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
One chewable tablet contains:
ACTIVE SUBSTANCE:
Pimobendan
1.25 mg
EXCIPIENTS:
For a full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Chewable tablet.
Oblong, scored, mottled brown tablets with fine white spots, embossed with Boehringer Ingelheim
logo and P01.
The tablet can be divided into equal halves.
4.
CLINICAL PARTICULARS
4.1
TARGET SPECIES
Dog
4.2
INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
For the treatment of canine congestive heart failure originating from dilated cardiomyopathy or
valvular insufficiency (mitral and/or tricuspid valve regurgitation).
(See also section 4.9).
4.3
CONTRAINDICATIONS
[The product] is not to be used in hypertrophic cardiomyopathies or in diseases in which an
improvement in cardiac output cannot be achieved for functional or anatomical reasons (e.g. aortic
stenosis).
Since [the product] is metabolised mainly via the liver, it should not be used in dogs with severe
impairment of liver function (see also 4.7).
3
4.4
SPECIAL WARNINGS
None.
4.5
SPECIAL PRECAUTIONS FOR USE
SPECIAL PREC
Read the complete document
